A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-000046-19

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to demonstrate that rivaroxaban is superior to placebo in subjects with HF and significant CAD, who are receiving standard care, in reducing the risk of the composite of ACM, MI, or stroke following an index event.


Critère d'inclusion

  • Prevention of death, heart attack and stroke in patients with heart failure and significant coronary artery disease following an episode of decompensated HF (index event)